UY29392A1 - Metodos para el tratamiento de la angiogenesis ocular, el edema retinal, la isquemia retinal y la retinopatia diabetica mediante el uso de inhibidores selectivos de los receptores de la tirosinquinasa. - Google Patents

Metodos para el tratamiento de la angiogenesis ocular, el edema retinal, la isquemia retinal y la retinopatia diabetica mediante el uso de inhibidores selectivos de los receptores de la tirosinquinasa.

Info

Publication number
UY29392A1
UY29392A1 UY29392A UY29392A UY29392A1 UY 29392 A1 UY29392 A1 UY 29392A1 UY 29392 A UY29392 A UY 29392A UY 29392 A UY29392 A UY 29392A UY 29392 A1 UY29392 A1 UY 29392A1
Authority
UY
Uruguay
Prior art keywords
retinal
treatment
methods
diabetic retinopathy
thirosinquinase
Prior art date
Application number
UY29392A
Other languages
English (en)
Inventor
David P Bingaman
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of UY29392A1 publication Critical patent/UY29392A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

El presente invento brinda composiciones y métodos para el tratamineto de la neovascularización ocular la angiogénesis, el edema retinal, la retinopatía diabética y/o la esquemia retinal a los efectos de prevenir la pérdida de agudeza visual asociada con dichas afecciones. Más especialmete, el presente invento brinda composiciones que contienen inhibidores del receptor de la tirosinquinasa que presentan perfiles de enlace exclusivos y su utilización en el tratamieto de trastornos oculares.
UY29392A 2005-02-23 2006-02-23 Metodos para el tratamiento de la angiogenesis ocular, el edema retinal, la isquemia retinal y la retinopatia diabetica mediante el uso de inhibidores selectivos de los receptores de la tirosinquinasa. UY29392A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65567605P 2005-02-23 2005-02-23

Publications (1)

Publication Number Publication Date
UY29392A1 true UY29392A1 (es) 2006-05-31

Family

ID=36659886

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29392A UY29392A1 (es) 2005-02-23 2006-02-23 Metodos para el tratamiento de la angiogenesis ocular, el edema retinal, la isquemia retinal y la retinopatia diabetica mediante el uso de inhibidores selectivos de los receptores de la tirosinquinasa.

Country Status (15)

Country Link
US (1) US20060189608A1 (es)
EP (2) EP1850839A2 (es)
JP (2) JP2008531593A (es)
KR (1) KR20070106031A (es)
CN (2) CN101163465A (es)
AR (1) AR054229A1 (es)
AU (1) AU2006216567B2 (es)
BR (1) BRPI0609241A2 (es)
CA (1) CA2598692A1 (es)
MX (1) MX2007009942A (es)
RU (2) RU2396956C2 (es)
TW (1) TW200640443A (es)
UY (1) UY29392A1 (es)
WO (1) WO2006091801A2 (es)
ZA (1) ZA200707493B (es)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108545A1 (en) * 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
US6448077B1 (en) * 1994-02-10 2002-09-10 Imclone Systems, Inc. Chimeric and humanized monoclonal antibodies specific to VEGF receptors
AU2002316305A1 (en) * 2001-06-20 2003-01-08 Vlaams Interuniversitair Institut Voor Biotechnologie Method of treating atherosclerosis and other inflammatory diseases
ES2299590T3 (es) * 2001-08-10 2008-06-01 Imclone Systems, Inc. Uso medico de celulas madre que expresan vegfr-1.ng vegfr-1.
SI1819358T1 (sl) 2004-11-18 2014-10-30 Imclone Llc Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1)
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
EP2336117A1 (en) 2005-05-26 2011-06-22 Neuron Systems, Inc Heterocyclic compounds for treating retinal diseases
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070173538A1 (en) * 2005-12-23 2007-07-26 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2007076454A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. Pharmaceutical formulation for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
US20070149480A1 (en) * 2005-12-23 2007-06-28 Alcon, Inc. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US8197435B2 (en) 2006-05-02 2012-06-12 Emory University Methods and devices for drug delivery to ocular tissue using microneedle
CN101563051A (zh) * 2006-12-18 2009-10-21 爱尔康研究有限公司 眼用药物递送的装置与方法
US20090105245A1 (en) * 2006-12-21 2009-04-23 Bingaman David P Methods for treating macular edema and ocular angiogenesis using an anti-inflammatory agent and a receptor tyrosine kinase inhibitor
US20080153819A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for treating macular edema and pathologic ocular angiogenesis using a neuroprotective agent and a receptor tyrosine kinase inhibitor
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
WO2008156752A2 (en) * 2007-06-18 2008-12-24 The National Retina Institute Vitreous biomarkers and related diagnostics and therapeutics
EP2170949B1 (en) 2007-07-17 2012-12-26 F. Hoffmann - La Roche AG Variable tangential flow filtration
JP2010534201A (ja) * 2007-07-20 2010-11-04 アルコン，インコーポレイテッド 受容体チロシンキナーゼ阻害（ＲＴＫｉ）化合物の目への送達のための医薬製剤
TWI580441B (zh) * 2008-09-19 2017-05-01 愛爾康研究有限公司 穩定的藥學次微米懸浮液及其形成方法
TW201023912A (en) 2008-12-05 2010-07-01 Alcon Res Ltd Pharmaceutical suspension
CN104887389B (zh) 2009-01-29 2017-06-23 弗赛特影像4股份有限公司 后段给药
WO2010101971A1 (en) * 2009-03-03 2010-09-10 Alcon Research, Ltd. Pharmaceutical composition for delivery of receptor tyrosine kinase inhibiting (rtki) compounds to the eye
WO2010101989A1 (en) 2009-03-03 2010-09-10 Alcon Research, Ltd. PHARMACEUTICAL COMPOSITION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
ES2508290T3 (es) * 2009-03-03 2014-10-16 Alcon Research, Ltd. Composición farmacéutica para la administracón de compuestos de inhibición del receptor de tirosina cinasa (RTKI) al ojo
US9458198B1 (en) 2009-06-26 2016-10-04 Shire Orphan Therapies Gmbh Cyclic peptide-based NPR-B agonists
US8551938B2 (en) * 2009-09-25 2013-10-08 Alcon Research, Ltd. NPR-B agonists
AU2010298256B2 (en) * 2009-09-25 2015-08-13 Takeda Pharmaceutical Company Limited Novel NPR-B agonists
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
TW201121995A (en) 2009-12-18 2011-07-01 Alcon Res Ltd Novel NPR-B agonists
WO2011075471A2 (en) 2009-12-18 2011-06-23 Alcon Research, Ltd. Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders
US10166142B2 (en) 2010-01-29 2019-01-01 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
AU2011271518A1 (en) * 2010-07-02 2012-12-13 Alcon Research, Ltd. Compounds for the treatment of posterior segment disorders and diseases
SI2600930T1 (sl) 2010-08-05 2021-08-31 Forsight Vision4, Inc. Injekcijska naprava za dajanje zdravila
EP2627292B1 (en) 2010-10-15 2018-10-10 Clearside Biomedical, Inc. Device for ocular access
WO2012068549A2 (en) 2010-11-19 2012-05-24 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
RU2481839C2 (ru) * 2011-08-16 2013-05-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет Министерства здравоохранения и социального развития" Способ лечения ишемической болезни сердца с дистальным или диффузным поражением коронарных артерий
US9883968B2 (en) 2011-09-16 2018-02-06 Forsight Vision4, Inc. Fluid exchange apparatus and methods
SG11201503637SA (en) 2012-11-08 2015-06-29 Clearside Biomedical Inc Methods and devices for the treatment of ocular diseases in human subjects
SG11201504859YA (en) 2012-12-20 2015-07-30 Aldeyra Therapeutics Inc Peri-carbinols
SG11201505587YA (en) 2013-01-23 2015-08-28 Aldeyra Therapeutics Inc Toxic aldehyde related diseases and treatment
WO2014116593A1 (en) 2013-01-25 2014-07-31 Aldexa Therapeutics, Inc. Novel traps in the treatment of macular degeneration
ES2831625T3 (es) 2013-02-20 2021-06-09 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos
WO2014152959A1 (en) 2013-03-14 2014-09-25 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
CN105246529B (zh) 2013-05-03 2019-06-14 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
EP3003454B1 (en) 2013-06-03 2020-01-08 Clearside Biomedical, Inc. Apparatus for drug delivery using multiple reservoirs
EP3030239A4 (en) 2013-06-11 2017-03-08 Kala Pharmaceuticals, Inc. Urea derivatives and uses thereof
WO2015196085A2 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
WO2016022750A1 (en) 2014-08-08 2016-02-11 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
USD750223S1 (en) 2014-10-14 2016-02-23 Clearside Biomedical, Inc. Medical injector for ocular injection
CA2969467A1 (en) 2014-12-10 2016-06-16 Kala Pharmaceuticals, Inc. 1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
RU2598348C1 (ru) * 2015-09-23 2016-09-20 Федеральное государственное бюджетное учреждение "Московский научно-исследовательский институт глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации Способ лечения экспериментальной ретинопатии недоношенных
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US11129823B2 (en) 2016-05-09 2021-09-28 Aldeyra Therapeutics, Inc. Combination treatment of ocular inflammatory disorders and diseases
WO2018031913A1 (en) 2016-08-12 2018-02-15 Clearside Biomedical, Inc. Devices and methods for adjusting the insertion depth of a needle for medicament delivery
JP2019534269A (ja) * 2016-10-14 2019-11-28 ノバルティス アーゲー Ｃｓｆ−１ｒの阻害剤を使用して眼疾患を治療するための方法
EP3576770A1 (en) 2017-02-01 2019-12-11 Shire Human Genetic Therapies, Inc. Compounds and compositions for the treatment of ophthalmic disorders
ES2968462T3 (es) 2017-03-16 2024-05-09 Aldeyra Therapeutics Inc Sal polimórfica de 6-cloro-3-amino-2(2-hidroxiprolil) quinolina y usos de la misma
WO2018182527A1 (en) * 2017-03-30 2018-10-04 National University Of Singapore Method for treating inflammatory complications in eye diseases
WO2018204515A1 (en) 2017-05-02 2018-11-08 Georgia Tech Research Corporation Targeted drug delivery methods using a microneedle
RU2652342C1 (ru) * 2017-07-13 2018-04-25 Наталья Александровна Гаврилова Композиция для лечения ретинальной неоваскуляризации в эксперименте и способ лечения с ее использованием
US11040039B2 (en) 2017-10-10 2021-06-22 Aldeyra Therapeutics, Inc. Treatment of inflammatory disorders
WO2019103906A1 (en) 2017-11-21 2019-05-31 Forsight Vision4, Inc. Fluid exchange apparatus for expandable port delivery system and methods of use
RU2675021C1 (ru) * 2018-02-01 2018-12-14 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения хронической ишемической ретинопатии
EP3833660A4 (en) 2018-08-06 2022-05-11 Aldeyra Therapeutics, Inc. POLYMORPHIC COMPOUNDS AND THEIR USES
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
JP2022530967A (ja) 2019-05-02 2022-07-05 アルデイラ セラピューティクス， インコーポレイテッド 多形化合物およびその使用
JP2023526016A (ja) 2020-05-13 2023-06-20 アルデイラ セラピューティクス， インコーポレイテッド 医薬製剤およびその使用
WO2022226347A1 (en) * 2021-04-23 2022-10-27 AmMax Bio, Inc. Treatment of ophthalmic diseases
USD1033637S1 (en) 2022-01-24 2024-07-02 Forsight Vision4, Inc. Fluid exchange device

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6155378A (ja) 1984-08-27 1986-03-19 Ebara Corp 振動柱ポンプ
GB8703367D0 (en) 1987-02-13 1987-03-18 Lister Shearing Equip Ltd Clipper blade assembly
JPH0368228A (ja) 1989-08-07 1991-03-25 Nippon Telegr & Teleph Corp <Ntt> 無瞬断切り替え方法
JP2809441B2 (ja) 1989-08-23 1998-10-08 松下電器産業株式会社 衛星放送受信機
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6028099A (en) * 1998-03-13 2000-02-22 John Hopkins University, School Of Medicine Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
EP1178791A2 (en) * 1999-05-07 2002-02-13 Johns Hopkins University School of Medicine The use of a protein tyrosine kinase pathway inhibitor in the treatment of ocular disorders
JP2003535038A (ja) * 1999-12-30 2003-11-25 スージェン・インコーポレーテッド 蛋白質キナーゼ活性の調節および癌化学療法において用いるための３−ヘテロアリーリデニル−２−インドリノン化合物
MXPA02007632A (es) * 2000-02-07 2004-08-23 Abbott Gmbh & Co Kg Derivados de 2-benzotiazolil urea y su uso como inhibidores de proteina cinasa.
DE10023485A1 (de) * 2000-05-09 2001-11-22 Schering Ag Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
AU2687702A (en) * 2000-10-17 2002-04-29 Merck & Co Inc Orally active salts with tyrosine kinase activity
EP1425284A2 (en) 2001-09-11 2004-06-09 Smithkline Beecham Corporation Furo- and thienopyrimidine derivatives as angiogenesis inhibitors
AU2002341881B2 (en) * 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
EP1434774A1 (en) * 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
US20030225273A1 (en) * 2002-03-21 2003-12-04 Michaelides Michael R. Thiopyrimidine and isothiazolopyrimidine kinase inhibitors
US7166722B2 (en) * 2002-10-21 2007-01-23 Kirin Beer Kabushiki Kaisha N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n′-(5-methyl-3-isoxazolyl)urea salt in crystalline form
US7297709B2 (en) * 2003-05-22 2007-11-20 Abbott Laboratories Indazole, benzisoxazole, and benzisothiazole kinase inhibitors
CN1826324B (zh) * 2003-05-22 2011-12-07 雅培制药有限公司 吲唑、苯并异*唑和苯并异噻唑激酶抑制剂
US20040235892A1 (en) * 2003-05-22 2004-11-25 Yujia Dai Indazole and benzisoxazole kinase inhibitors
RU2244532C1 (ru) * 2003-07-01 2005-01-20 Государственное учреждение Межотраслевой научно-технический комплекс "Микрохирургия глаза" им. акад. С.Н. Федорова Способ хирургического фотодинамического лечения субретинальных неоваскулярных мембран (варианты)
WO2007076358A1 (en) * 2005-12-23 2007-07-05 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
US20080153818A1 (en) * 2006-12-21 2008-06-26 Bingaman David P Methods for preventing inflammation during surgery

Also Published As

Publication number Publication date
KR20070106031A (ko) 2007-10-31
US20060189608A1 (en) 2006-08-24
RU2396956C2 (ru) 2010-08-20
JP2008531593A (ja) 2008-08-14
JP2012062333A (ja) 2012-03-29
RU2010113675A (ru) 2011-10-20
AU2006216567A1 (en) 2006-08-31
CA2598692A1 (en) 2006-08-31
EP1850839A2 (en) 2007-11-07
WO2006091801A2 (en) 2006-08-31
CN103110951A (zh) 2013-05-22
ZA200707493B (en) 2008-12-31
AU2006216567B2 (en) 2011-10-13
BRPI0609241A2 (pt) 2010-03-09
TW200640443A (en) 2006-12-01
EP2594264A1 (en) 2013-05-22
WO2006091801A3 (en) 2007-03-15
CN101163465A (zh) 2008-04-16
AR054229A1 (es) 2007-06-13
RU2007135390A (ru) 2009-03-27
MX2007009942A (es) 2008-01-30
RU2445096C2 (ru) 2012-03-20

Similar Documents

Publication Publication Date Title
UY29392A1 (es) Metodos para el tratamiento de la angiogenesis ocular, el edema retinal, la isquemia retinal y la retinopatia diabetica mediante el uso de inhibidores selectivos de los receptores de la tirosinquinasa.
CR8711A (es) Indazoles, benzotiazoles, benzoisotiazoles, benzisoxazoles y preparacion y usos de estos
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
CL2011000488A1 (es) Compuestos derivados de pirazolo-pirimidinas sustituidas; composicion y combinacion farmaceutica que los comprenden; y su uso como inhibidores de pde9 para el tratamiento, alivio y/o prevencion de deterioros cognitivos relacionados con la percepcion, alzheimer,trastornos del sueño, trastorno bipolar, diabetes mellitus.
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
CL2008002744A1 (es) Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2.
CR10309A (es) &#34;compuestos y composiciones como inhibidores de la actividad del receptor canabinoide 1&#34;
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
ECSP067093A (es) Derivados de sulfamato y sulfamida para el tratamiento de epilepsia y trastornos relacionados
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
ECSP066877A (es) Moduladores canabinoides de tetrahidro-indazol
EA201071291A2 (ru) Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств
GT201400222A (es) Agentes para tratar trastornos que implican la modulación de receptores de rianodina
WO2009105534A3 (en) Ophthalmic nsaids as adjuvants
UY31570A1 (es) Derivados de oxadiazol agonistas del receptor s1p1. composiciones farmacéuticas que lo comprenden y procedimientos de preparacion de los mismos
DOP2005000038A (es) Derivados de piridilo y su uso como antagonistas del receptor mglu5&#34;
CR10314A (es) Compuestos que tienen actividad en el receptor m 1 y sus usos en medicina
UY39188A (es) Imidazopiridazinas como moduladores de il-17
GT201000179A (es) &#34;antagonistas del receptor mineralcorticoide y metodos de uso&#34;
DOP2011000081A (es) Benzamida sustituida como ligandos del receptor de canabinoides
ECSP11011204A (es) Compuestos de quinazolina sustituidos
AR074369A1 (es) Anticuerpos anti-unc 5b (receptor de netrina) y metodos de uso
CR11500A (es) Derivados ciclopropilamina
MX2007010752A (es) Usos oftalmicos de moduladores de receptor s1p.
CL2007002386A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento y/o profilaxis de enfermedades seleccionadas de degeneracion macular, neovascularizacion o angiogenesis de la cornea, iris o retina, retinopatia diabetica y no diabetica.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20161213